Advances in Antiviral Delivery Systems and Chitosan-Based Polymeric and Nanoparticulate Antivirals and Antiviral Carriers

Dominika, Žigrayová; Mikušová, Veronika; Mikuš, Peter

doi:10.3390/v15030647

Cited by 21 publications

(15 citation statements)

References 251 publications

(280 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current attempts to design clinical therapies for viral infection usually inhibit viral replication using small-molecule drugs; nevertheless, their efficacy is limited by poor bioavailability, nontargeted release, and adverse side effects (35,36). Many kinds of delivery systems such as micelles, nanoliposomes, nanoemulsions, and biopolymer NPs can be designed to enhance the efficacy of antiviral drugs by overcoming the above obstacles (37)(38)(39). However, IAV infection activates the host's natural immune response.…”

Section: Discussionmentioning

confidence: 99%

Polydopamine-based nanomedicines for efficient antiviral and secondary injury protection therapy

Yin

Zhang

et al. 2023

Sci. Adv.

View full text Add to dashboard Cite

Viral infections continue to threaten human health. It remains a major challenge to efficiently inhibit viral infection while avoiding secondary injury. Here, we designed a multifunctional nanoplatform (termed as ODCM), prepared by oseltamivir phosphate (OP)–loaded polydopamine (PDA) nanoparticles camouflaged by the macrophage cell membrane (CM). OP can be efficiently loaded onto the PDA nanoparticles through the π-π stacking and hydrogen bonding interactions with a high drug-loading rate of 37.6%. In particular, the biomimetic nanoparticles can accumulate actively in the damaged lung model of viral infection. At the infection site, PDA nanoparticles can consume excess reactive oxygen species and be simultaneously oxidized and degraded to achieve controlled release of OP. This system exhibits enhanced delivery efficiency, inflammatory storm suppression, and viral replication inhibition. Therefore, the system exerts outstanding therapeutic effects while improving pulmonary edema and protecting lung injury in a mouse model of influenza A virus infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Polydopamine-based nanomedicines for efficient antiviral and secondary injury protection therapy

Yin

Zhang

et al. 2023

Sci. Adv.

View full text Add to dashboard Cite

show abstract

“…Many studies have been carried out to evaluate the delivery of peptides and proteins, including thyrotropin-releasing hormone, octreotide, desmopressin, vasopressin, uroguanferin, calcitonin, exenatide, human insulin, parathyroid hormone, leptin, interferon, and ovalbumin using different polymers [ 59 ]. Various chitosan-based delivery systems, such as microparticles, nanoparticles, liposomes, and niosomes have been developed to deliver proteins [ 60 , 61 , 62 ]. In fact, chitosan is actively studied as a vehicle for oral insulin drug delivery, which is economical and more suitable to patients compared with injectables [ 63 ].…”

Section: Applicability Of Chitosan-oriented Multifarious Deliverymentioning

confidence: 99%

Chitosan in Oral Drug Delivery Formulations: A Review

Sangnim,

Dheer,

Jangra

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Nanoformulations have become increasingly useful as drug delivery technologies in recent decades. As therapeutics, oral administration is the most common delivery method, although it is not always the most effective route because of challenges with swallowing, gastrointestinal discomfort, low solubility, and poor absorption. One of the most significant barriers that medications must overcome to exert a therapeutic effect is the impact of the first hepatic transit. Studies have shown that controlled-release systems using nanoparticles composed of biodegradable natural polymers significantly improve oral administration, which is why these materials have attracted significant attention. Chitosan possesses a wide variety of properties and functions in the pharmaceutical as well as healthcare industries. Drug encapsulation and transport within the body are two of its most important features. Moreover, chitosan can enhance drug efficacy by facilitating drug interaction with target cells. Based on its physicochemical properties, chitosan can potentially be synthesized into nanoparticles, and this review summarizes recent advances and applications of orally delivered chitosan nanoparticle interventions.

show abstract

“…In particular, CS nanoparticles have a great potential for application in the treatment of COVID-19, considering the characteristics of this biopolymer, which include low toxicity, biodegradability, suitable physical properties, and mucoadhesive property. In particular, when CS is positively charged and interacts with the mucosa, it is able to open the tight junctions between cells, thereby increasing drug permeation [ 151 , 152 ]. There are also reports that CS has anti-SARS-CoV-2 activity [ 153 ].…”

Section: Chitosan-based Nanoparticles For Pulmonary Deliverymentioning

confidence: 99%

Advancements in Chitosan-Based Nanoparticles for Pulmonary Drug Delivery

Zacaron,

Silva,

Costa

et al. 2023

Polymers

View full text Add to dashboard Cite

The evolution of respiratory diseases represents a considerable public health challenge, as they are among the leading causes of death worldwide. In this sense, in addition to the high prevalence of diseases such as asthma, chronic obstructive pulmonary disease, pneumonia, cystic fibrosis, and lung cancer, emerging respiratory diseases, particularly those caused by members of the coronavirus family, have contributed to a significant number of deaths on a global scale over the last two decades. Therefore, several studies have been conducted to optimize the efficacy of treatments against these diseases, focusing on pulmonary drug delivery using nanomedicine. Thus, the development of nanocarriers has emerged as a promising alternative to overcome the limitations of conventional therapy, by increasing drug bioavailability at the target site and reducing unwanted side effects. In this context, nanoparticles composed of chitosan (CS) show advantages over other nanocarriers because chitosan possesses intrinsic biological properties, such as anti-inflammatory, antimicrobial, and mucoadhesive capacity. Moreover, CS nanoparticles have the potential to enhance drug stability, prolong the duration of action, improve drug targeting, control drug release, optimize dissolution of poorly soluble drugs, and increase cell membrane permeability of hydrophobic drugs. These properties could optimize the performance of the drug after its pulmonary administration. Therefore, this review aims to discuss the potential of chitosan nanoparticles for pulmonary drug delivery, highlighting how their biological properties can improve the treatment of pulmonary diseases, including their synergistic action with the encapsulated drug.

show abstract

Advances in Antiviral Delivery Systems and Chitosan-Based Polymeric and Nanoparticulate Antivirals and Antiviral Carriers

Cited by 21 publications

References 251 publications

Polydopamine-based nanomedicines for efficient antiviral and secondary injury protection therapy

Polydopamine-based nanomedicines for efficient antiviral and secondary injury protection therapy

Chitosan in Oral Drug Delivery Formulations: A Review

Advancements in Chitosan-Based Nanoparticles for Pulmonary Drug Delivery

Contact Info

Product

Resources

About